KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.

J Clin Oncol · 2026-Feb-20 · PMID 41512237

Panel Patients_at_Risk_Table质量警告待 EXE 对齐验证

Figure 1

Figure 1. a) 3-year Progression-Free survival (PFS) in adolescent patients with advanced stage cHL by study arm b) 3-year Progression-Free survival (PFS) in adolescent patients with Stage III cHL by study arm c) 3-year Progression-Free survival (PFS) in adolescent patients with Stage IV cHL by study arm d) 3-year Event-Free Survival by study arm, where events on N-AVD were due to non-protocol chemotherapy prior to progression (n=4); non protocol RT prior to progression (n=1) or progression of disease (n=9). With BV-AVD events were due to non-protocol chemotherapy prior to progression (n=1); non-protocol RT prior to progression (n=1) and progression of disease (n=22) and death (n=1). Note: the 95% CI for the hazard ratio (HR) is two-sided.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.72
质量通过否
预期曲线2
实际曲线1
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T16:57:55+00:00